Navigation Links
Omnicell Announces Fourth Quarter and Full Year 2011 Results

MOUNTAIN VIEW, Calif., Jan. 26, 2012 /PRNewswire/ -- Omnicell, Inc. (NASDAQ: OMCL), a leading provider of system solutions to healthcare facilities, today announced results for its fourth quarter and year ended December 31, 2011.

GAAP results: Revenue for the fourth quarter of 2011 was $62.9 million, up $5.7 million or 9.9% from the fourth quarter of 2010 and down $1.5 million or 2.3% from the third quarter of 2011. Revenue for the year ended December 31, 2011 was $245.5 million, up $23.1 million or 10.4% from the year ended December 31, 2010.

Fourth quarter 2011 net income as reported in accordance with U.S. generally accepted accounting principles (GAAP) was $4.1 million, or $0.12 per diluted share. This compares to net income of $0.7 million, or $0.02 per diluted share in the fourth quarter of 2010 and net income of $3.0 million, or $0.09 per diluted share in the third quarter of 2011. For the year ended December 31, 2011, net income was $10.4 million, or $0.30 per diluted share. This compares to net income of $4.9 million, or $0.15 per diluted share for the year ended December 31, 2010.

Non-GAAP results: Non-GAAP net income was $6.4 million for the fourth quarter of 2011, or $0.19 per diluted share. Non-GAAP net income for the fourth quarter excludes $2.2 million of stock-based compensation expense. This compares to non-GAAP net income of $3.6 million, or $0.11 per diluted share for the fourth quarter of 2010, excluding $2.6 million of stock-based compensation expense and $0.4 million of income tax expense on the repatriation of profits from India associated with the facilities consolidation announced in the third quarter of 2010. Fourth quarter 2011 results compare to non-GAAP net income of $5.4 million, or $0.16 per diluted share for the third quarter of 2011, excluding $2.4 million of stock-based compensation expense. Non-GAAP net income was $20.5 million for the year ended December 31, 2011, or $0.60 per diluted share, excluding $9.5 million of stock-based compensation expense and $1.0 million of pre-tax litigation claims settlement expense, net of a $0.4 million tax effect. Non-GAAP net income was $14.5 million for the year ended December 31, 2010, or $0.43 per diluted share, excluding $9.0 million of stock-based compensation expense, a $2.4 million gain ($1.4 million, net of tax) related to the settlement of litigation claims, and $2.7 million of charges ($2.0 million, net of tax) related to restructuring, reduction-in-force and repatriation of profits from India associated with the facilities consolidation.

Product backlog as of December 31, 2011 totaled $134 million, up $7 million or 6% from December 31, 2010.

"Overall, 2011 was a very good year for Omnicell," said Randall Lipps, Omnicell's President, CEO, and Chairman of the Board. "Revenue was up 10%, non-GAAP net income was up 42%, and although year ending backlog was lower than expectations, backlog grew 6% from 2010. I'm very happy with our introduction of new products, our growth of the customer base, and our entry into new markets during the year."

Omnicell Conference Call InformationOmnicell will hold a conference call at 1:30 p.m. PST today to discuss fourth quarter and 2011 year-end financial results. The conference call can be monitored by dialing 1-800-696-5518 within the U.S. or 1-706-758-4883 for all other locations. The Conference ID # is 44215896. Internet users can access the conference call at  A replay of the call will be available today at approximately 4:30 p.m. PST and will be available until 11:45 p.m. PST on February 3, 2012. The replay access numbers are 1-855-859-2056 within the U.S. and 1-404-537-3406 for all other locations, conference code # 44215896.

About OmnicellOmnicell, Inc. (NASDAQ: OMCL) is a leading provider of automated and business information solutions enabling hospitals and healthcare systems to streamline the medication administration process and manage costly medical supplies for increased operational efficiency and enhanced patient safety. Through seamless integration with a hospital's existing IT infrastructure, Omnicell solutions empower healthcare facilities to achieve comprehensive automation of medication and supply management from the arrival at the loading dock to the patient's bedside. Omnicell also provides healthcare facilities with business analytics software designed to improve medication diversion detection and regulatory compliance.

Since 1992, more than 2,200 hospital customers worldwide have relied on Omnicell's medication automation, supply chain, and hospital analytics solutions to increase patient safety, improve efficiency and address changing healthcare regulations while providing effective control of costs, charge capture for payer reimbursement and inventory management of medications and supplies.

For more information about Omnicell, please visit

Forward-Looking StatementsTo the extent any statements contained in this release deal with information that is not historical, these statements are necessarily forward-looking. As such, they are subject to the occurrence of many events outside Omnicell's control and are subject to various risk factors that could cause actual results to differ materially from those expressed or implied in any forward-looking statement. The risk factors are described in the Company's Securities and Exchange Commission (SEC) filings and include, without limitation, the unfavorable general economic and market conditions, volatility in the credit market, risks to growth and acceptance of our products and services and to growth of the clinical automation and workflow automation market generally, the potential of increasing competition, potential regulatory changes, and the ability of the company to improve sales productivity to grow product backlog, retain key personnel, to cut expenses, to manage future changes in revenue levels, to develop new products and integrate acquired companies, products or intellectual property in a timely and cost-effective manner. Prospective investors are cautioned not to place undue reliance on forward-looking statements.

Use of Non-GAAP Financial InformationThis press release contains financial measures that are not calculated in accordance with U.S. generally accepted accounting principles (GAAP). Our management evaluates and makes operating decisions using various performance measures. In addition to Omnicell's GAAP results, we also consider non-GAAP gross profit, non-GAAP operating expenses, non-GAAP net income, and non-GAAP net income per diluted share. Additionally, we calculate Adjusted EBITDA (another non-GAAP measure) by means of adjustments to GAAP Net Income. These non-GAAP results should not be considered as an alternative to gross profit, operating expenses, net income, net income per diluted share, or any other performance measure derived in accordance with GAAP.  We present these non-GAAP results because we consider them to be important supplemental measures of Omnicell's performance.

Our non-GAAP gross profit, non-GAAP operating expenses, non-GAAP net income, and non-GAAP net income per diluted share are exclusive of certain items to facilitate management's review of the comparability of Omnicell's core operating results on a period to period basis because such items are not related to Omnicell's ongoing core operating results as viewed by management. We define our "core operating results" as those revenues recorded in a particular period and the expenses incurred within that period that directly drive operating income in that period. Management uses these non-GAAP financial measures in making operating decisions because, in addition to meaningful supplemental information regarding operating performance, the measures give us a better understanding of how we should invest in research and development, fund infrastructure growth and evaluate the effectiveness of marketing strategies. In calculating the above non-GAAP results, management specifically adjusted for the following excluded items:

a) Stock-based compensation expense impact of Accounting Standards Codification (ASC) 718. We recognize equity plan-related compensation expenses, which represent the fair value of all share-based payments to employees, including grants of employee stock options, as required under ASC 718, "Stock Compensation" as non-GAAP adjustments in each period.

b) 2011 litigation settlement. We recorded an accrual in the first quarter of 2011 for settlement of litigation with Medacist Solutions Group, LLC for $1.0 million, which was paid in the second quarter of 2011. The net impact was $0.6 million after the $0.4 million income tax effect.

c) 2010 litigation settlement. In the third quarter of 2010 we settled two pending litigation matters with Flo Healthcare LLC (now part of InterMetro Industries Corporation), with payment to InterMetro of $2.7 million. The resulting $2.4 million credit to third quarter 2010 selling general and administrative expense reflected adjustment for the settlement with release of the liability in excess of the amounts settled.

d) 2010 restructuring charges In the third quarter of 2010 we incurred charges for restructuring and impairment in executing our plan for consolidation of our Bangalore, India and Woodlands, Texas offices with our California and Tennessee facilities. These charges consisted of severance for departing employees and relocation benefits for transferring employees, exit and disposal costs related to the closed facilities, and impairment of abandoned leasehold improvements.

e) 2010 reduction-in-force and other exit related charges. In the third quarter of 2010 we conducted a small reduction-in-force to rebalance the required workforce by function to our current business environment. Additionally, we incurred lease termination costs and leasehold improvement impairment costs (upon abandonment) in connection with merging our Lebanon, Tennessee office with our office in Nashville.

f) 2010 income taxes on repatriated foreign earnings. In the third quarter of 2010, the closure of our Bangalore, India office resulted in a charge for repatriation taxes and a valuation allowance against related deferred tax assets.

Management adjusts for the above items because management believes that, in general, these items possess one or more of the following characteristics: their magnitude and timing is largely outside of Omnicell's control; they are unrelated to the ongoing operation of the business in the ordinary course; they are unusual and we do not expect them to occur in the ordinary course of business; or they are non-operational or non-cash expenses involving stock option grants.

We believe that the presentation of these non-GAAP financial measures is warranted for several reasons:

1) Such non-GAAP financial measures provide an additional analytical tool for understanding Omnicell's financial performance by excluding the impact of items which may obscure trends in the core operating results of the business;

2) Since we have historically reported non-GAAP results to the investment community, we believe the inclusion of non-GAAP numbers provides consistency and enhances investors' ability to compare our performance across financial reporting periods;

3) These non-GAAP financial measures are employed by Omnicell's management in its own evaluation of performance and are utilized in financial and operational decision making processes, such as budget planning and forecasting; and

4) These non-GAAP financial measures facilitate comparisons to the operating results of other companies in our industry, which use similar financial measures to supplement their GAAP results, thus enhancing the perspective of investors who wish to utilize such comparisons in their analysis of our performance.

Set forth below are additional reasons why share-based compensation expense related to ASC 718 is excluded from our non-GAAP financial measures:

i)  While share-based compensation calculated in accordance with ASC 718 constitutes an ongoing and recurring expense of Omnicell, it is not an expense that requires cash settlement by Omnicell. We therefore exclude these charges for purposes of evaluating core operating results. Thus, our non-GAAP measurements are presented exclusive of stock-based compensation expense to assist management and investors in evaluating our core operating results.

ii) We present ASC 718 share-based payment compensation expense in our reconciliation of non-GAAP financial measures on a pre-tax basis because the exact tax differences related to the timing and deductibility of share-based compensation, under ASC 718 are dependent upon the trading price of Omnicell's common stock and the timing and exercise by employees of their stock options.  As a result of these timing and market uncertainties, the tax effect related to share-based compensation expense would be inconsistent in amount and frequency and is therefore excluded from our non-GAAP results.

Our Adjusted EBITDA calculation is defined as earnings before interest income and expense, taxes, depreciation and amortization, and non-cash expenses, including ASC 718 stock compensation expense.

As stated above, we present non-GAAP financial measures because we consider them to be important supplemental measures of performance. However, non-GAAP financial measures have limitations as an analytical tool and should not be considered in isolation or as a substitute for Omnicell's GAAP results.  In the future, we expect to incur expenses similar to certain of the non-GAAP adjustments described above and expect to continue reporting non-GAAP financial measures excluding such items. Some of the limitations in relying on non-GAAP financial measures are:

  • Omnicell's stock option and stock purchase plans are important components of incentive compensation arrangements and will be reflected as expenses in Omnicell's GAAP results for the foreseeable future under ASC 718.
  • Other companies, including other companies in Omnicell's industry, may calculate non-GAAP financial measures differently than Omnicell, limiting their usefulness as a comparative measure.

  • Pursuant to the requirements of SEC Regulation G, a detailed reconciliation between Omnicell's non-GAAP and GAAP financial results is set forth in the financial tables at the end of this press release. Investors are advised to carefully review and consider this information strictly as a supplement to the GAAP results that are contained in this press release and in Omnicell's SEC filings.

    OMCL-EOmnicell, Inc.Condensed Consolidated Statements of Operations(in thousands, except per share data)Three Months EndedYear EndedDecember 31,
    (unaudited)September 30,
    (unaudited)December 31,
    (unaudited)December 31,
    (unaudited)December 31,
     2010 (1)Revenues:Product$





    171,100Services and other revenues15,65014,64913,72759,67151,307Total revenue62,93164,43957,268245,535222,407Cost of revenues:Cost of product revenues19,57222,42918,64979,56776,372Cost of services and other revenues7,4807,5627,25630,18428,079Restructuring charges----39Total cost of revenues27,05229,99125,905109,751104,490Gross profit35,87934,44831,363135,784117,917Operating expenses:Research and development5,9036,0195,40322,04221,007Selling, general, and administrative23,80723,63524,43897,52086,227Restructuring charges----1,157Total operating expenses29,71029,65429,841119,562108,391Income from operations6,1694,7941,52216,2229,526Other income (expense), net(67)(191)145(133)431Income before provision for income taxes6,1024,6031,66716,0899,957Provision for income taxes1,9641,6099955,7005,065Net income $





    4,892Net income per share:Basic$










    0.15Weighted average shares outstanding:Basic33,09733,20932,99733,12332,651Diluted34,11434,21933,90034,10333,513(1)  Information derived from our December 31, 2010 audited Consolidated Financial Statements.Omnicell, Inc.Condensed Consolidated Balance Sheets(In thousands)December 31,December 31,20112010(unaudited)(1)ASSETSCurrent assets:Cash and cash equivalents$


    175,635Short-term investments8,1078,074Accounts receivable, net36,90242,732Inventories18,1079,785Prepaid expenses10,49511,959Deferred tax assets7,91413,052Other current assets6,1077,266Total current assets279,394268,503Property and equipment, net17,30714,351Non-current net investment in sales-type leases8,7859,224Goodwill28,54328,543Other intangible assets4,2314,672Non-current deferred tax assets13,9929,566Other assets9,7168,365Total assets$


    343,224LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable$


    13,242Accrued compensation7,3287,731Accrued liabilities7,0208,684Deferred service revenue19,19116,788Deferred gross profit14,21011,719Total current liabilities58,74958,164Long-term deferred service revenue18,96619,171Other long-term liabilities1,339675Total liabilities79,05478,010Stockholders' equity:Total stockholders' equity282,914265,214Total liabilities and stockholders' equity$


    Information derived from our December 31, 2010 audited Consolidated Financial Statements.Omnicell, Inc.Reconciliation of GAAP to Non-GAAP(In thousands, except per share data, unaudited)Three months endedDecember 31, 2011September 30, 2011December 31, 2010Net

    incomeNet income
    per share-
    incomeNet income
    per share-
    incomeNet income
    per share-






    0.02Non-GAAP adjustments:Taxes on repatriated foreign earnings--383ASC 718 share-based compensation adjustment (a)Gross profit290358356Operating expenses1,9552,0532,208Total after tax adjustments2,2450.072,4110.072,9470.09Non-GAAP$






    0.11(a) This adjustment reflects the accounting impact of non-cash stock-based compensation expense related to the impact of ASC 718 (formerly referred to as SFAS No. 123R) for the periods shown.Omnicell, Inc.Reconciliation of GAAP to Non-GAAP(In thousands, except per share data, unaudited)Year endedDecember 31, 2011December 31, 2010Net
    incomeNet income
    per share-
    incomeNet income
    per share-




    0.15Non-GAAP adjustments:Restructuring costGross profit-39Operating expenses-1,157Reduction-in-force, other exit-related chargesGross profit-285Operating expenses-219Litigation settlement (a)1,000(2,439)Subtotal pretax adjustments1,000(739)Income tax effect of non-GAAP adjustments(380)326Taxes on repatriated foreign earnings-957ASC 718 share-based compensation adjustment (b)Gross profit1,3981,350Operating expenses8,1017,665Total after tax adjustments10,1190.309,5590.28Non-GAAP$




    0.43(a) The 2011 adjustment is for the accrual of a $1.0 million pre-tax litigation settlement in operating expenses ($0.6 million, net of tax effect of $0.4 million) in the first quarter of 2011. The 2010 adjustment reflects the reversal in operating expenses for the settlement of litigation in the third quarter of 2010 for amounts less than accrued.(b) This adjustment reflects the accounting impact of non-cash stock-based compensation expense related to the impact of ASC 718 (formerly referred to as SFAS No. 123R) for the periods shown.Omnicell, Inc.Calculation of Adjusted EBITDA (1)(In thousands, unaudited)Three Months EndedYear EndedDecember 31,
    2011September 30,
    2011December 31,
    2010December 31,
    2011December 31,
    2010GAAP net income $





    4,892Add back:ASC 718 stock compensation expense2,2452,4112,5649,4999,015Restructuring charges----1,196Reduction-in-force, other exit-related charges----504Litigation settlement---1,000(2,439)Interest(21)(34)(79)(205)(420)Depreciation and amortization expense2,1632,0272,1307,9848,619Income tax expense1,9641,6099955,7005,065Non-GAAP adjusted EBITDA (1)$





    26,432(1)  Defined as earnings before interest income and expense, taxes, depreciation and amortization, and non-cash expenses, including stock compensation expense, per ASC 718, formerly FAS 123R.  Also excludes non-GAAP adjustments for restructuring, reduction-in-force and other exit-related charges, and litigation settlement.

    SOURCE Omnicell, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    2. Omnicell Announces Fourth Quarter and Full-Year 2009 Results
    3. Omnicell Selected by Nations Third Largest Public Healthcare System for Medication Management Systems
    4. Omnicells OmniLinkRx Honored With KLAS Award for Product Leadership
    5. Omnicells Automated Medication Dispensing System Honored With 2010 Best in KLAS Award
    6. Omnicells OmniCenter Achieves VMware Ready(TM) Healthcare Virtualization Status
    7. Omnicell Introduces New Omnicell Packager With WorkflowRx Software for Improved Pharmacy Efficiency
    8. Wellmont Health System Selects Omnicell for Best-in-Class Medication Management
    9. Deaconess Health System Selects Omnicells Medication Management System for Product Reliability and Improved Patient Care
    10. Omnicell Acquires Pandora Data Systems
    11. Omnicell to Release Third Quarter 2010 Earnings Results on October 27
    Post Your Comments:
    (Date:10/11/2017)... PARK, Calif. , Oct. 11, 2017  BioPharmX ... national scientific team that developed an innovative way to ... quantity of the delivery of new drugs. ... 2017 Fall Clinical Dermatology Conference will show how researchers ... General Hospital, Harvard Medical School used a suite of ...
    (Date:10/10/2017)... COUNTY, Calif. , Oct. 10, 2017  NDS received FDA ... Mobile  — a medical-grade battery-powered display stand specifically designed for endoscopy ... to transform technology into a clinical solution to support the improvement ... Innovative Design ... ZeroWire Mobile Wireless Solution ...
    (Date:10/4/2017)... Korea , Oct. 4, 2017  South Korean-based ... next-generation CPR training aide "cprCUBE" on Kickstarter. The device ... compression during cardiac arrests with better efficiency compared to ... also offers real-time feedback on efficacy of the compression ... crowdfunding campaign has a goal to raise $5,000. ...
    Breaking Medicine Technology:
    (Date:10/13/2017)... N.J. (PRWEB) , ... October 13, 2017 , ... The ... Holly Day Market. Featuring a collection of specialty vendors and unique items from across ... personalized and quality-focused health and wellness services offered by the VNA. The boutique ...
    (Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... DevOps and Agile Software Development, has been awarded a contract by the Center ... Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in ...
    (Date:10/12/2017)... New Orleans, LA (PRWEB) , ... October 12, 2017 , ... ... fitness centers in the U.S., announced today its plans to open a flagship location ... club will occupy the former Rooms To Go store next to Office Depot in ...
    (Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... drug delivery system that we intend to develop to enable prevention of a ... lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss ...
    (Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and Grand ... Best and Brightest in Wellness® by Best and Brightest. OnSite Wellness will be ... Oct. 20 from 7:30 a.m. to 2 p.m. at the Henry Autograph Collection ...
    Breaking Medicine News(10 mins):